drugset / Trial / NCT04519385
Toclizumam Versus Dexamethasone in Severe Covid-19 Cases
RandomizedParallel-groupDouble-blindTreatment
Summary
randomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19
Timeline
- Start
- 2020-03-01
- Primary completion
- 2020-07-01
- Completion
- 2020-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 8 mg | Other |
| Subject | Tocilizumab | Monoclonal antibody | 4 mg/kg | — |